Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

241

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

March 31, 2019

Conditions
Alzheimer's Disease
Interventions
DRUG

Donepezil

Eligible patients were treated with Aricept® 10 mg/day for 20 weeks of study period. Aricept® should be taken at night, just prior to sleeping. If patient cannot endure 10mg/d,the dose could be reduce to 5mg/d for 4 weeks and then increase back to 10mg/d. Patients who could not endure the 10mg/d titration the 2nd time and were put back to 5mg/d or discontinuance of Aricept® should be considered as withdrawal from the study. There were a visit (visit 1) at week 0, the end of week 4 (visit 2) and the end of week 20 (visit 3), respectively.

Trial Locations (1)

Unknown

Beijing Friendship Hospital, Capital Medical University, Beijing

All Listed Sponsors
collaborator

Eisai China Inc.

INDUSTRY

collaborator

Xuanwu Hospital, Beijing

OTHER

lead

Beijing Friendship Hospital

OTHER

NCT02787746 - Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter